Precision Therapeutics raises $33 million in Series D financing

06/14/2010 | American City Business Journals

Precision Therapeutics secured $33 million in a Series D funding round, led by venture capital firm Bain Capital. Precision will use the proceeds to boost the growth of ChemoFx, a technology that helps identify a type of chemotherapy that is likely to benefit an individual cancer patient, and develop genomics-based products.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC